Joan M. Bathon
A5042617054- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Osteoarthritis Treatment and Mechanisms
- Viral Infections and Immunology Research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Monoclonal and Polyclonal Antibodies Research
- Spondyloarthritis Studies and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lower Extremity Biomechanics and Pathologies
- Biosimilars and Bioanalytical Methods
- Sarcoidosis and Beryllium Toxicity Research
- T-cell and B-cell Immunology
- Total Knee Arthroplasty Outcomes
- Musculoskeletal synovial abnormalities and treatments
- Systemic Sclerosis and Related Diseases
- Cardiac Imaging and Diagnostics
- Atherosclerosis and Cardiovascular Diseases
- Peptidase Inhibition and Analysis
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Cytokine Signaling Pathways and Interactions
- Musculoskeletal Disorders and Rehabilitation
- Inflammatory mediators and NSAID effects
Columbia University
2015-2025
Columbia University Irving Medical Center
2013-2025
Texas Health Dallas
2020-2024
New York Hospital Queens
2017-2024
NewYork–Presbyterian Hospital
2017-2024
Presbyterian Hospital
2017-2021
American University of Beirut
2021
Yale University
2017
National Institutes of Health
2017
Johns Hopkins University
2004-2015
Etanercept, which blocks the action of tumor necrosis factor, reduces disease activity in patients with long-standing rheumatoid arthritis. Its efficacy reducing and preventing joint damage active early arthritis is unknown.
Abstract Objective To compare the benefits of initiating treatment with methotrexate (MTX) and infliximab (anti–tumor necrosis factor α [anti‐TNFα] monoclonal antibody) those MTX alone in patients rheumatoid arthritis (RA) ≤3 years' duration. Methods RA were eligible if they had active disease no prior or a TNFα inhibitor. One thousand forty‐nine randomly assigned 4:5:5 ratio to 3 groups: MTX–placebo, MTX–3 mg/kg infliximab, MTX–6 infliximab. dosages rapidly escalated 20 mg/week, placebo...
<h3>Objectives</h3> To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing most recent developments in field. <h3>Methods</h3> An international task force was formed and solicited three systematic literature research activities on safety efficacy disease-modifying antirheumatic drugs (DMARDs) glucocorticoids (GCs). The new evidence discussed light last from 2019. A predefined voting process applied to each overarching principle recommendation....
This criteria set has been approved by the American College of Rheumatology (ACR) Board Directors and European League Against Rheumatism (EULAR) Executive Committee as Provisional.This signifies that quantitatively validated using patient data, but it not undergone validation based on an external data set.All ACR/EULAR-approved sets are expected to undergo intermittent updates.The is independent, professional, medical scientific society which does guarantee, warrant, or endorse any...
Abstract Objective To compare the clinical and radiographic outcomes in patients with rheumatoid arthritis (RA) who received monotherapy either etanercept or methotrexate (MTX) for 2 years to assess safety of this therapy. Methods In Enbrel ERA (early arthritis) trial, 632 early, active RA were randomized receive twice‐weekly subcutaneous (10 mg 25 mg) weekly oral MTX (mean dosage 19 per week) at least 1 year a double‐blind manner. Following blinded phase 512 continued therapy which they had...
Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there no widely used definition of remission that stringent achievable and could be applied uniformly as outcome measure clinical trials. This work was undertaken to develop such a definition. Methods A committee consisting members the American College Rheumatology, European League Against Rheumatism, Outcome Measures Rheumatology Initiative met guide process review prespecified analyses from RA The...
Abstract Objective To identify disease characteristics leading to progression of joint damage in patients with early rheumatoid arthritis (RA) treated methotrexate (MTX) versus those infliximab plus MTX. Methods Patients who had not previously been MTX active RA were randomly assigned receive escalating doses up 20 mg/week placebo or at weeks 0, 2, and 6, every 8 thereafter through week 46. Radiographic was assessed using the modified Sharp/van der Heijde score (SHS). The relationship...
To assess whether it is better to intensively treat all patients with early rheumatoid arthritis (RA) using combinations of drugs or reserve this approach for who do not have an appropriate response (as determined by a Disease Activity Score in 28 joints the erythrocyte sedimentation rate [DAS28-ESR] ≥ 3.2 at week 24) methotrexate (MTX) monotherapy, and combination therapy MTX plus etanercept superior sulfasalazine hydroxychloroquine.The Treatment Early Aggressive Rheumatoid Arthritis (TEAR)...
<h3>Objectives:</h3> To assess the efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis (RA) poor prognostic factors. <h3>Methods:</h3> In this double-blind, phase IIIb study, RA for 2 years or less were randomly assigned 1 : to receive (∼10 mg/kg) plus methotrexate, placebo methotrexate. Patients seropositive factor (RF), anti-cyclic citrullinated protein (CCP) type both had radiographic evidence joint erosions. The co-primary endpoints proportion...
Abstract Objective To determine the safety and efficacy of additional courses rituximab in patients with rheumatoid arthritis (RA). Methods An open‐label extension analysis RA previously treated was conducted. Patients who had participated any 3 double‐blind trials were eligible for (2 infusions 1,000 mg given 2 weeks apart) if they exhibited a swollen joint count tender ≥8 ≥16 elapsing after previous course. Safety assessed receiving all or portion Efficacy 24 each course, using American...
<h3>Objectives</h3> The interleukin-6 receptor (IL-6R) blocker tocilizumab (TCZ) reduces inflammatory disease activity in rheumatoid arthritis (RA) but elevates lipid concentrations some patients. We aimed to characterise the impact of IL-6R inhibition on established and novel risk factors active RA. <h3>Methods</h3> Randomised, multicentre, two-part, phase III trial (24-week double-blind, 80-week open-label), MEASURE, evaluated lipoprotein levels, high-density (HDL) particle composition,...
Introduction Postoperative infections, such as periprosthetic septic arthritis, postoperative osteomyelitis, and deep-wound infection, are a particularly devastating complication of orthopedic surgery. They incur significant morbidity in terms patient suffering disability, prolonged hospitalization, frequent need for additional surgical procedures, delay rehabilitation. Moreover, there is 3-fold increase mortality procedures complicated by joint sepsis or osteomyelitis (1). The use...
To examine the association of radiographic progression and disease activity states in patients with rheumatoid arthritis (RA) treated methotrexate or without infliximab.Patients (n = 1049) active RA for 3 years less no previous treatment were randomly assigned (4 : 5 5) to receive plus placebo infliximab 6 mg/kg at weeks 0, 2 6, every 8 thereafter week 46. Disease was classified by simplified index as remission (< =3.3), low (>3.3 < =11), moderate (>11 =26), high (>26). Radiographic measured...
To compare measures of body fat and lean mass the prevalence abnormal composition phenotypes (sarcopenia, overfat, sarcopenic obesity) in men women with rheumatoid arthritis (RA) versus matched controls, to explore disease-related predictors patients RA.A total 189 RA age-, sex-, race-matched non-RA controls underwent dual-energy x-ray absorptiometry for measurement regional mass. Continuous categorical were compared between control subjects by sex according categories index (BMI). Within...
Osteoarthritis (OA) clinical practice guidelines identify a substantial therapeutic role for physical activity, but objective information about the activity of this population is lacking. The aim study was to objectively measure levels in adults with knee OA and report prevalence meeting public health guidelines.
To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and American College Rheumatology (ACR).The project followed EULAR standardized operating procedures, which use a three-step approach: 1) expert-based definition relevant research questions (November 2006); 2) systematic literature search 2006 May 2007); 3) expert consensus based results (May 2007). In addition, since this is...
<h3>Objective:</h3> To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and American College Rheumatology (ACR). <h3>Methods:</h3> The project followed EULAR standardised operating procedures, which use a three-step approach: (1) expert-based definition relevant research questions (November 2006); (2) systematic literature search 2006 May 2007); (3) expert consensus based results...
<h3>Background</h3> Interstitial lung disease (ILD) is associated with high morbidity and mortality in rheumatoid arthritis (RA). Citrullinated proteins are observed RA tissues; however, the association of specific anticitrullinated peptide antibodies (ACPA) ILD unknown. <h3>Methods</h3> patients underwent multidetector CT (MDCT) chest, from which features a semiquantitative Score (ILDS; range 0–32) were assessed. Anti-CCP (CCP2) levels panel against 17 citrullinated four non-citrullinated...